Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Revenue - OtherShares OutstandingShares Outstanding
Ratios

Lyra Therapeutics (LYRA) Shares Issued (2021 - 2024)

Lyra Therapeutics has reported Shares Issued over the past 4 years, most recently at $3000.0 for Q1 2024.

  • Quarterly results put Shares Issued at $3000.0 for Q1 2024, down 25.0% from a year ago — trailing twelve months through Dec 2024 was $3000.0 (down 97.09% YoY), and the annual figure for FY2024 was $3000.0, down 97.09%.
  • Shares Issued for Q1 2024 was $3000.0 at Lyra Therapeutics, up from $2000.0 in the prior quarter.
  • Over the last five years, Shares Issued for LYRA hit a ceiling of $331000.0 in Q2 2021 and a floor of $2000.0 in Q3 2023.
  • Median Shares Issued over the past 4 years was $9500.0 (2021), compared with a mean of $89750.0.
  • Biggest five-year swings in Shares Issued: plummeted 96.95% in 2022 and later fell 25.0% in 2024.
  • Lyra Therapeutics' Shares Issued stood at $11000.0 in 2021, then dropped by 27.27% to $8000.0 in 2022, then crashed by 75.0% to $2000.0 in 2023, then soared by 50.0% to $3000.0 in 2024.
  • The last three reported values for Shares Issued were $3000.0 (Q1 2024), $2000.0 (Q3 2023), and $97000.0 (Q2 2023) per Business Quant data.